Stifel Nicolaus lowers its rating on Idenix IDIX to Sell from Hold as data does not support lofty expectations after Hep C hype.
Stifel Nicolaus says, "We are downgrading Idenix shares from Hold to Sell. Idenix shares have more
than doubled as a result of the recent M&A tailwind in the hepatitis C (HCV) development space that has emphasized demand for nucleotide-based assets. However, we believe the significant difference in potency that exists between IDX-184 and Pharmasset's PSI-7977 and Inhibitex's INX-189 has meaningful implications on how the remaining potential consolidators of the space strategically view the longer-term competitiveness and ROI of a 2-drug vs. 3-drug regimen. We think that fundamental difference in potency negatively impacts valuation and believe the risk/reward profile at current levels is now disproportionately skewed to the downside."
IDIX closed at $14.33 a share.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in